Advances in atopic dermatitis in 2015

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 6, 2016, Pages 1548-1555

  Nomura, Takashi ^a,b   Kabashima, Kenji ^a,c,d  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c AGENCY FOR SCIENCE   (Singapore)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

adiposity; aryl hydrocarbon receptor; Atopic dermatitis; biologics; chemoattractant receptor homologous molecule expressed on TH2 cells; chemokines; cytokines; extracellular signal regulated kinase; filaggrin; Janus kinase; JTE 052; pathogenic effector TH2; petrolatum; signal transducer and activator of transcription 3; sirtuin 1; TH1; TH17; TH2; TH22; thymic stromal lymphopoietin; transepidermal water loss; ultraviolet B

Indexed keywords

ALLERGEN; BIOLOGICAL PRODUCT; FILAGGRIN; KYNURENINE; PREBIOTIC AGENT; THYMIC STROMAL LYMPHOPOIETIN; CLAUDIN; DESMOPLAKIN; JANUS KINASE;

ANALYTICAL PARAMETERS; ATOPIC DERMATITIS; BASIC RESEARCH; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; GENE LOCUS; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; INNATE IMMUNITY; METABOLITE; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SKIN SENSITIZATION; SKIN WATER LOSS; SLEEP DISORDER; SYSTEMIC DISEASE; T LYMPHOCYTE; ANIMAL; ARTHRITIS, RHEUMATOID; DERMATITIS, ATOPIC; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; NEWBORN; OBESITY; PHYSIOLOGY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TH2 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; CLAUDINS; DERMATITIS, ATOPIC; DESMOPLAKINS; HUMANS; IMMUNITY, INNATE; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; JANUS KINASES; MOLECULAR TARGETED THERAPY; OBESITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TH2 CELLS;

EID: 85001090533     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.10.004     Document Type: Review

References (59)

1. 1 Weidinger, S., Novak, N., Atopic dermatitis. Lancet 387 (2016), 1109–1122.
2. 2 Egawa, G., Kabashima, K., Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march. J Allergy Clin Immunol 138 (2016), 350–358.e1.
3. 3 Thaci, D., Simpson, E.L., Beck, L.A., Bieber, T., Blauvelt, A., Papp, K., et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387 (2016), 40–52.
4. 4 Tokura, Y., Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 58 (2010), 1–7.
5. 5 Henriksen, L., Simonsen, J., Haerskjold, A., Linder, M., Kieler, H., Thomsen, S.F., et al. Incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in Danish and Swedish children. J Allergy Clin Immunol 136 (2015), 360–366.e2.
6. 6 O'Donovan, S.M., Hourihane, J.O.'B., Murray, D.M., Kenny, L.C., Khashan, A.S., Chaoimh, C.N., et al. Neonatal adiposity increases the risk of atopic dermatitis during the first year of life. J Allergy Clin Immunol 137 (2016), 108–117.
7. 7 Schmitt, J., Schwarz, K., Baurecht, H., Hotze, M., Folster-Holst, R., Rodriguez, E., et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol 137 (2016), 130–136.
8. 8 Yamanaka, K., Mizutani, H., “Inflammatory skin march”: IL-1-mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events. J Allergy Clin Immunol 136 (2015), 823–824.
9. 9 Gao, L., Bin, L., Rafaels, N.M., Huang, L., Potee, J., Ruczinski, I., et al. Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. J Allergy Clin Immunol 136 (2015), 1591–1600.
10. 10 Fishbein, A.B., Vitaterna, O., Haugh, I.M., Bavishi, A.A., Zee, P.C., Turek, F.W., et al. Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J Allergy Clin Immunol 136 (2015), 1170–1177.
11. 11 Silverberg, J.I., Association between childhood eczema and headaches: an analysis of 19 US population-based studies. J Allergy Clin Immunol 137 (2016), 492–499.e5.
12. 12 Silverberg, J.I., Greenland, P., Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol 135 (2015), 721–728.e6.
13. 13 Kim, K.W., Myers, R.A., Lee, J.H., Igartua, C., Lee, K.E., Kim, Y.H., et al. Genome-wide association study of recalcitrant atopic dermatitis in Korean children. J Allergy Clin Immunol 136 (2015), 678–684.e4.
14. 14 Schaarschmidt, H., Ellinghaus, D., Rodriguez, E., Kretschmer, A., Baurecht, H., Lipinski, S., et al. A genome-wide association study reveals 2 new susceptibility loci for atopic dermatitis. J Allergy Clin Immunol 136 (2015), 802–806.
15. 15 Taylan, F., Nilsson, D., Asad, S., Lieden, A., Wahlgren, C.F., Winge, M.C., et al. Whole-exome sequencing of Ethiopian patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol 136 (2015), 507–509.e19.
16. 16 Suarez-Farinas, M., Ungar, B., Correa da Rosa, J., Ewald, D.A., Rozenblit, M., Gonzalez, J., et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 135 (2015), 1218–1227.
17. 17 McAleer, M.A., Pohler, E., Smith, F.J., Wilson, N.J., Cole, C., MacGowan, S., et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol 136 (2015), 1268–1276.
18. 18 Yu, H.S., Kang, M.J., Kwon, J.W., Lee, S.Y., Lee, E., Yang, S.I., et al. Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and production of IgE. J Allergy Clin Immunol 135 (2015), 827–830.e5.
19. 19 Correa da Rosa, J., Malajian, D., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., et al. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. J Allergy Clin Immunol 135 (2015), 712–720.
20. 20 Czarnowicki, T., Esaki, H., Gonzalez, J., Malajian, D., Shemer, A., Noda, S., et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol 136 (2015), 941–951.e3.
21. 21 Leung, D.Y., Atopic dermatitis: age and race do matter!. J Allergy Clin Immunol 136 (2015), 1265–1267.
22. 22 Noda, S., Suarez-Farinas, M., Ungar, B., Kim, S.J., de Guzman Strong, C., Xu, H., et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 136 (2015), 1254–1264.
23. 23 Czarnowicki, T., Malajian, D., Shemer, A., Fuentes-Duculan, J., Gonzalez, J., Suarez-Farinas, M., et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. J Allergy Clin Immunol 136 (2015), 208–211.
24. 24 Czarnowicki, T., Gonzalez, J., Shemer, A., Malajian, D., Xu, H., Zheng, X., et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol 136 (2015), 104–115.e7.
25. 25 Mitson-Salazar, A., Yin, Y., Wansley, D.L., Young, M., Bolan, H., Arceo, S., et al. Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human TH2 cell subpopulation with enhanced function. J Allergy Clin Immunol 137 (2016), 907–918.e9.
26. 26 Czarnowicki, T., Gonzalez, J., Bonifacio, K.M., Shemer, A., Xiangyu, P., Kunjravia, N., et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol 137 (2016), 118–129.e5.
27. 27 Hradetzky, S., Roesner, L.M., Heratizadeh, A., Crameri, R., Garbani, M., Scheynius, A., et al. Differential cytokine induction by the human skin-associated autoallergen thioredoxin in sensitized patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 135 (2015), 1378–1380 e1-5.
28. 28 Saunders, S.P., Moran, T., Floudas, A., Wurlod, F., Kaszlikowska, A., Salimi, M., et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J Allergy Clin Immunol 137 (2016), 482–491.
29. 29 Mashiko, S., Bouguermouh, S., Rubio, M., Baba, N., Bissonnette, R., Sarfati, M., Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol 136 (2015), 351–359.e1.
30. 30 Wang, Q., Du, J., Zhu, J., Yang, X., Zhou, B., Thymic stromal lymphopoietin signaling in CD4(+) T cells is required for TH2 memory. J Allergy Clin Immunol 135 (2015), 781–791.e3.
31. 31 Fornasa, G., Tsilingiri, K., Caprioli, F., Botti, F., Mapelli, M., Meller, S., et al. Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. J Allergy Clin Immunol 136 (2015), 413–422.
32. 32 Harden, J.L., Lewis, S.M., Lish, S.R., Suarez-Farinas, M., Gareau, D., Lentini, T., et al. The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. J Allergy Clin Immunol 137 (2016), 1830–1840.
33. 33 Kelleher, M., Dunn-Galvin, A., Hourihane, J.O., Murray, D., Campbell, L.E., McLean, W.H., et al. Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol 135 (2015), 930–935.e1.
34. 34 Tauber, M., Balica, S., Hsu, C.Y., Jean-Decoster, C., Lauze, C., Redoules, D., et al. Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. J Allergy Clin Immunol 137 (2016), 1272–1274.e3.
35. 35 Song, H., Yoo, Y., Hwang, J., Na, Y.C., Kim, H.S., Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol 137 (2016), 852–860.
36. 36 Campana, R., Moritz, K., Marth, K., Neubauer, A., Huber, H., Henning, R., et al. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. J Allergy Clin Immunol 137 (2016), 601–609.e8.
37. 37 Esaki, H., Ewald, D.A., Ungar, B., Rozenblit, M., Zheng, X., Xu, H., et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 135 (2015), 153–163.
38. 38 Werfel, T., Heratizadeh, A., Niebuhr, M., Kapp, A., Roesner, L.M., Karch, A., et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 136 (2015), 96–103.e9.
39. 39 Gruber, C., van Stuivenberg, M., Mosca, F., Moro, G., Chirico, G., Braegger, C.P., et al. Immunoactive prebiotics transiently prevent occurrence of early atopic dermatitis among low-atopy-risk infants. J Allergy Clin Immunol 136 (2015), 1696–1698.e1.
40. 40 Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol 136 (2015), 667–677.e7.
41. 41 Thyssen, J.P., Zirwas, M.J., Elias, P.M., Potential role of reduced environmental UV exposure as a driver of the current epidemic of atopic dermatitis. J Allergy Clin Immunol 136 (2015), 1163–1169.
42. 42 Czarnowicki, T., Malajian, D., Khattri, S., Correa da Rosa, J., Dutt, R., Finney, R., et al. Petrolatum: barrier repair and antimicrobial responses underlying this “inert” moisturizer. J Allergy Clin Immunol 137 (2016), 1091–1102.e7.
43. 43 Kim, J.H., Bae, H.C., Ko, N.Y., Lee, S.H., Jeong, S.H., Lee, H., et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol 136 (2015), 205–208.e9.
44. 44 Seltmann, J., Roesner, L.M., von Hesler, F.W., Wittmann, M., Werfel, T., IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 135 (2015), 1659–1661.e4.
45. 45 Ming, M., Zhao, B., Shea, C.R., Shah, P., Qiang, L., White, S.R., et al. Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 135 (2015), 936–945.e4.
46. 46 Riethmuller, C., McAleer, M.A., Koppes, S.A., Abdayem, R., Franz, J., Haftek, M., et al. Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis. J Allergy Clin Immunol 136 (2015), 1573–1580 e1-2.
47. 47 Thyssen, J.P., Tang, L., Husemoen, L.L., Stender, S., Szecsi, P.B., Menne, T., et al. Filaggrin gene mutations are not associated with food and aeroallergen sensitization without concomitant atopic dermatitis in adults. J Allergy Clin Immunol 135 (2015), 1375–1378.e1.
48. 48 Brough, H.A., Liu, A.H., Sicherer, S., Makinson, K., Douiri, A., Brown, S.J., et al. Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol 135 (2015), 164–170.
49. 49 Noda, S., Krueger, J.G., Guttman-Yassky, E., The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 135 (2015), 324–336.
50. 50 Li, H., Li, C., Zhang, H., Zhang, L., Cheng, R., Li, M., et al. Effects of lidocaine on regulatory T cells in atopic dermatitis. J Allergy Clin Immunol 137 (2016), 613–617.e5.
51. 51 Shin, H.W., Kim, D.K., Park, M.H., Eun, K.M., Lee, M., So, D., et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 135 (2015), 1476–1485.e7.
52. 52 Werfel, T., Heratizadeh, A., Aberer, W., Ahrens, F., Augustin, M., Biedermann, T., et al. S2k guideline on diagnosis and treatment of atopic dermatitis—short version. Allergo J Int 25 (2016), 82–95.
53. 53 Kabashima, K., New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 70 (2013), 3–11.
54. 54 Wawrzyniak, P., Akdis, C.A., Finkelman, F.D., Rothenberg, M.E., Advances and highlights in mechanisms of allergic disease in 2015. J Allergy Clin Immunol 137 (2016), 1681–1696.
55. 55 Werfel, T., Allam, J.P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 138 (2016), 336–349.
56. 56 Spergel, J.M., From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 105 (2010), 99–106 quiz 107-9.
57. 57 Dharmage, S.C., Lowe, A.J., Matheson, M.C., Burgess, J.A., Allen, K.J., Abramson, M.J., Atopic dermatitis and the atopic march revisited. Allergy 69 (2014), 17–27.
58. 58 Marenholz, I., Esparza-Gordillo, J., Ruschendorf, F., Bauerfeind, A., Strachan, D.P., Spycher, B.D., et al. Meta-analysis identifies seven susceptibility loci involved in the atopic march. Nat Commun, 6, 2015, 8804.
59. 59 Nakajima, S., Kitoh, A., Egawa, G., Natsuaki, Y., Nakamizo, S., Moniaga, C.S., et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol 134 (2014), 2122–2130.